Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01495598 · OUTCOME

Time to Maximum Observed Serum Concentration of Pomalidomide (Cmax)

Pomalidomide for Kaposi Sarcoma in People With or Without HIV · Source last updated 2022-11-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
hours
Interval / dispersion
Full Range
Time frame
At pre-dose, 1, 2, 3, 4, 6, and 8 hours after dose on Cycle 1 Day 1, and pre-dose, 1, 2, 3, 4, 6, 8, and 24 hours after dose on Cycle 1 Day 15.

What was measured

Time to maximum observed serum concentration of Pomalidomide was reported.

Groups in this outcome

All Participants - Pomalidomide 5mg Daily

All participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Participants - Pomalidomide 5mg Daily28

Reported measurements

Cycle 1 Day 1
Values in hours · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
All Participants - Pomalidomide 5mg Daily2.00Not reported18Not reported
Cycle 1 day 15
Values in hours · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
All Participants - Pomalidomide 5mg Daily2.08Not reported18Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1
        upper Limit
        8
        value
        2.00
    title
    Cycle 1 Day 1
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1
        upper Limit
        8
        value
        2.08
    title
    Cycle 1 day 15
denoms
  1. counts
    1. group Id
      OG000
      value
      28
    units
    Participants
description
Time to maximum observed serum concentration of Pomalidomide was reported.
dispersion Type
Full Range
groups
  1. description
    All participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.
    id
    OG000
    title
    All Participants - Pomalidomide 5mg Daily
param Type
MEDIAN
reporting Status
POSTED
time Frame
At pre-dose, 1, 2, 3, 4, 6, and 8 hours after dose on Cycle 1 Day 1, and pre-dose, 1, 2, 3, 4, 6, 8, and 24 hours after dose on Cycle 1 Day 15.
title
Time to Maximum Observed Serum Concentration of Pomalidomide (Cmax)
type
PRIMARY
unit Of Measure
hours

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice